TrialBMC cancer2020

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.

Carlotta Antoniotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.